<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335281</url>
  </required_header>
  <id_info>
    <org_study_id>TMMU-DP-GI-FMT-001</org_study_id>
    <nct_id>NCT02335281</nct_id>
  </id_info>
  <brief_title>Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease</brief_title>
  <acronym>SFMT-IBD</acronym>
  <official_title>Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanling Wei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are many limitations in the current treatments of Inflammatory bowel disease (IBD). Now&#xD;
      the investigators realized that the intestinal microecological is closely associated with the&#xD;
      development of IBD. So the standardized fecal microbiota transplantation is considered to be&#xD;
      simple but effective emerging therapies for the treatment of IBD. In this project the&#xD;
      investigators intend to carry out a single-center, randomized, single-blind clinical&#xD;
      intervention study. The investigators will recruit 40 patients with IBD (20 cases of&#xD;
      Ulcerative Colitis and 20 cases of Crohn's disease) in China. The patients will be randomly&#xD;
      divided into 2 groups, one group will be given treatment of standardized fecal microbiota&#xD;
      transplantation, the other will be simply treated with mesalazine, followed up for at least 1&#xD;
      year. The investigators propose to determine the efficiency, durability and safety of&#xD;
      Standardized Fecal Microbiota Transplantation for IBD treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this projects the investigators aim to re-establish a gut balance of intestinal&#xD;
      microecological through Standardized Fecal Microbiota Transplantation for IBD (UC and CD). We&#xD;
      will establish a standardized isolation, store, and transportion steps of fecal bacteria from&#xD;
      donated fresh stool in the laboratory. Then the bacteria will be transplanted to mid-gut by&#xD;
      nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized&#xD;
      FMT only once or traditional medicine of mesalazine and would be followed up for at least 1&#xD;
      year. The clinical symptoms, sign, blood tests, abdominal CT, endoscopy and questionnaire&#xD;
      will be used to assess the efficiency, durability and safety of Standardized FMT at the start&#xD;
      and end of the projects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission (defined as HBI score ≦ 4)</measure>
    <time_frame>up to one year</time_frame>
    <description>Clinical remission defined as HBI score ≦ 4. The endpoint of follow-up is the time of clinical recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization days</measure>
    <time_frame>up to one year</time_frame>
    <description>Hospitalization days from administration to discharge when at clinical remission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Standardized FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>Standardized FMT once</description>
    <arm_group_label>Standardized FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine</intervention_name>
    <description>2g Po perday</description>
    <arm_group_label>Mesalazine</arm_group_label>
    <other_name>Mesalamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe IBD define as HBI score ≥ 9.&#xD;
&#xD;
          -  Moderate IBD define as 7&lt;HBI &lt;9&#xD;
&#xD;
          -  Montreal classification: Age &gt; 14 years old, Location L1-3, Behavior B1-3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diarrhea activity scores &lt; 3&#xD;
&#xD;
          -  Severely active disease with perianal diseases&#xD;
&#xD;
          -  Severely active disease with indication of surgery.&#xD;
&#xD;
          -  Diagnosis as IBD first time or first year.&#xD;
&#xD;
          -  No history of using 5-ASA, biological (antibody), immunomodulatory therapy,&#xD;
             corticosteroid therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongfeng Chen, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongfeng Chen, doctor</last_name>
    <phone>86-13883032812</phone>
    <email>chedf1981@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanling Wei, doctor</last_name>
    <phone>86-15310354666</phone>
    <email>lingzi016@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology, Research Institute of Surgery, Da ping Hospital, The Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongfeng Chen, doctor</last_name>
      <phone>86-13883032812</phone>
      <email>chendf1981@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanling Wei, doctor</last_name>
      <phone>86-15310354666</phone>
      <email>lingzi016@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Yanling Wei</investigator_full_name>
    <investigator_title>Department of Gastroenterology, Research Institute of Surgery, Da ping Hospital, The Third Military Medical University</investigator_title>
  </responsible_party>
  <keyword>Standardized Fecal Microbiota Transplantation</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Crohn's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

